SG10201601719RA - Anti-LAG-3 Antibodies - Google Patents

Anti-LAG-3 Antibodies

Info

Publication number
SG10201601719RA
SG10201601719RA SG10201601719RA SG10201601719RA SG10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA
Authority
SG
Singapore
Prior art keywords
lag
antibodies
anti
Prior art date
Application number
SG10201601719RA
Inventor
Cheng-I Wang
Siok Ping Yeo
Chia Yin Lee
Hsueh Ling Janice Oh
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201601719RA priority Critical patent/SG10201601719RA/en
Publication of SG10201601719RA publication Critical patent/SG10201601719RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201601719RA 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies SG10201601719RA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
TW106107003A TW201734042A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibodies
PCT/EP2017/055060 WO2017149143A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
CN201780015245.3A CN109219619A (en) 2016-03-04 2017-03-03 anti-LAG-3 antibody
AU2017226965A AU2017226965A1 (en) 2016-03-04 2017-03-03 Anti-LAG-3antibodies
JP2018546454A JP2019517773A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibody
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
US16/079,947 US20190040136A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
KR1020187028534A KR20180114218A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibody
CA3015938A CA3015938A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
EP17710682.0A EP3423492A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Publications (1)

Publication Number Publication Date
SG10201601719RA true SG10201601719RA (en) 2017-10-30

Family

ID=58277259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Country Status (10)

Country Link
US (1) US20190040136A1 (en)
EP (1) EP3423492A1 (en)
JP (1) JP2019517773A (en)
KR (1) KR20180114218A (en)
CN (1) CN109219619A (en)
AU (1) AU2017226965A1 (en)
CA (1) CA3015938A1 (en)
SG (2) SG10201601719RA (en)
TW (1) TW201734042A (en)
WO (1) WO2017149143A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228926A1 (en) 2017-02-10 2018-08-16 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2018222711A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2019092181A1 (en) 2017-11-10 2019-05-16 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0615451T3 (en) 1992-05-26 2006-04-24 Immunex Corp Novel cytokine that binds to CD30
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-human antibody cytotoxic to cancer cells that express the ErbB2 receptor.
CN1638800A (en) 2002-01-09 2005-07-13 米德列斯公司 Human monoclonal antibodies against CD30
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1 (PD-1) as well as methods of treating cancer using the anti-PD-1 antibodies alone or in combination with other immunotherapies
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
ES2661952T3 (en) 2006-08-04 2018-04-04 Medimmune Limited human antibodies against ERBB2
WO2008059491A1 (en) 2006-11-13 2008-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et da la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2706926A1 (en) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
KR20190069615A (en) 2008-12-09 2019-06-19 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP2013534813A (en) 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Anti cd133 antibody single chain variable fragments, and use thereof
CN103221427B (en) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 Ox40 anti-antibody method and use thereof
RU2668170C2 (en) 2011-04-25 2018-09-26 Дайити Санкио Компани, Лимитед Anti-b7-h3-antibody
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
JP6271432B2 (en) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Anti-ErbB3 antibody and uses thereof
EP2773651A4 (en) 2011-11-03 2015-08-12 Univ Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EP2958942A1 (en) 2013-02-20 2015-12-30 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US10344088B2 (en) * 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
SI3178849T1 (en) 2013-09-20 2019-06-28 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments

Also Published As

Publication number Publication date
KR20180114218A (en) 2018-10-17
TW201734042A (en) 2017-10-01
CA3015938A1 (en) 2017-09-08
AU2017226965A1 (en) 2018-10-11
WO2017149143A1 (en) 2017-09-08
EP3423492A1 (en) 2019-01-09
SG11201807252QA (en) 2018-09-27
CN109219619A (en) 2019-01-15
US20190040136A1 (en) 2019-02-07
JP2019517773A (en) 2019-06-27

Similar Documents

Publication Publication Date Title
TWI576353B (en) Multispecific antibodies
AP201709765A0 (en) Anti-tigit antibodies
IL256844D0 (en) Pd-1 antibodies
EP3177649A4 (en) Anti-pd-l1 antibodies
IL256803D0 (en) Novel anti-pd-l1 antibodies
IL255727D0 (en) Novel anti-pd-l1 antibodies
RS58440B1 (en) Conjugated compounds comprising cysteine-engineered antibodies
EP3411410A4 (en) Pd-1 antibodies
IL257062D0 (en) Novel anti-pd-1 antibodies
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
SG11201705552QA (en) Anti-pd-l1 antibodies
IL247277D0 (en) Ebola monoclonal antibodies
ZA201608875B (en) Humanized anti-tau antibodies
ZA201800435B (en) Monoclonal antibodies against bcma
SG11201700496WA (en) Anti-pd-1 antibodies
IL251248D0 (en) Anti-interleukin-33 antibodies and uses thereof
IL258284D0 (en) Anti-lag3 antibodies and uses thereof
EP3212231A4 (en) Anti-tim-3 antibodies
IL251963D0 (en) Anti-pd-1 antibodies
IL257263D0 (en) Anti-angptl8 antibodies and uses thereof
EP3212229A4 (en) Anti-tim-3 antibodies
EP3334757A4 (en) Anti-tigit antibodies
GB201410825D0 (en) Anti-axl antibodies
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
TWI621628B (en) Il-8-binding antibodies and uses thereof